The new service gives Houstonians a direct line to Hartford, the capital of Connecticut. Photo via aveloair.com

When it made its debut in June, soaring out of Houston's Hobby Airport, Avelo Airlines gave Houstonians another connection to the Northeast via a nonstop flight to New Haven, Connecticut (HVN) (also known as the Pizza Express). Now, the airline has announced another Northeast route that will begin this fall: Houston to Hartford's Bradley International Airport (BDL).

The airline will offer flights twice each week, on Mondays and Fridays, beginning November 15 on Boeing Next-Generation 737 aircraft. Fares will begin at $98. It cements Avelo's status as the only airline flying nonstop from Houston to Connecticut.

"We are excited to debut our second route from Houston," Avelo Airlines founder and CEO Andrew Levyin said in a statement. "I am very encouraged by the response to our inaugural service between Houston and New Haven, Connecticut, and I'm optimistic we'll see a positive response on both ends of this route, as well. We're already hearing from our customers how excited they are about the convenience, affordability, and reliability Avelo is introducing to Houston."

The new service gives Houstonians a direct line to Hartford, the capital of Connecticut. Its location means travelers can easily access the mountains and arts districts of Massachusetts' Berkshires, the rural beauty of western Connecticut, as well as small, picturesque towns just over the Connecticut line into New York. Hartford is also within striking distance to some of Connecticut's most popular attractions, including the Mark Twain House and Museum, performing arts centers, and more. It's also about an hour away from Providence, Rhode Island, making it a gateway to the Ocean State's beaches and attractions in Newport and beyond.

"This addition provides even more options for travelers seeking convenient and affordable connections between Houston and the Northeast. Following the success of their Hobby Airport to Tweed-New Haven route, this new flight further strengthens Hobby Airport's position as a leading regional travel hub," said Jim Szczesniak, director of aviation for Houston airports.

Avelo Airlines ranked No. 1 in on-time performance and achieved the lowest flight cancellation rate in the industry during the first half of 2024, according to results reported by Anuvu, a leading aviation data services company.The low-cost carrier offers seat assignments for an additional fee, and reserves one-third of its cabin as seats with extra legroom.

Customers may also opt to pay extra for things like priority boarding, checked bags, carry-on overhead bags, and bringing a pet in the cabin. There are no extra fees to change or cancel reservations, and the airline automatically seats children under the age of 14 with an accompanying adult for no extra charge.

------

This article originally ran on CultureMap.

Eight Houston entrepreneurs are among 16 recipients of EOY’s Gulf South Award, which recognizes leaders of high-growth companies in Central Texas, South Texas, Louisiana, and Mississippi. Photo via Getty Images

8 Houston entrepreneurs recognized on annual EY awards program

regional winners

Eight Houston-area entrepreneurs have been named regional winners in Ernst & Young’s 2024 Entrepreneur Of The Year program.

The eight entrepreneurs are among 16 recipients of EOY’s Gulf South Award, which recognizes leaders of high-growth companies in Central Texas, South Texas, Louisiana, and Mississippi.

A panel of judges chose the winners based on factors such as:

  • Creation of long-term value through entrepreneurship.
  • Commitment to the purpose of their business.
  • Demonstration of growth and “substantial impact.”

“The 2024 Entrepreneur Of The Year Gulf South Award winners are exceptional business leaders fueling innovation within their industries and growth within their companies,” says Anna Horndahl, an EY partner who is co-director of EOY’s Gulf South program.

The Houston area’s Gulf South winners for 2024 are:

  • Hal Brumfield of Tachus Fiber Internet, a provider of fiber-to-the-home internet service based in The Woodlands.
  • Stuart Hinchen and Peter Jenkins of QuVa Pharma, a Sugar Land-based provider of ready-to-administer injectables.
  • Andrew Levy of Avelo Airlines, a low-cost airline based in Houston.
  • Derek Maetzold of Castle Biosciences, a Friendswood-based provider of diagnostic tests.
  • Shannon Payne of Allied Fire Protection, a Pearland-based provider of fire prevention products and services.
  • John Poindexter of JB Poindexter & Co., a Houston-based provider of automotive and manufacturing goods and services.
  • Ting Qiao of Wan Bridge, a Houston-based developer and operator of build-to-rent communities.

“These entrepreneurs are shining examples of how to lead a scaling business and also care for their employees, customers and communities,” says Travis Garms, an EY partner who is co-director of EOY’s Gulf South program.

The regional winners now qualify for consideration in the EOY national awards program. The national awards are scheduled to be presented in November.

The 17 finalists are competing for Ernst & Young’s Entrepreneur Of The Year 2024 Gulf South Award. Photo via Getty Images

17 Houston entrepreneurs named finalists in annual regional competition

on to the next round

Entrepreneurs from the Houston area have been named finalists for one of the region’s most prestigious business awards.

The 17 finalists are competing for Ernst & Young’s Entrepreneur Of The Year 2024 Gulf South Award. The Gulf South region includes parts of Texas, along with Louisiana and Mississippi.

An independent panel of judges selected the 48 finalists. Contenders were evaluated based on their demonstration of building long-term value through factors such as entrepreneurial spirit, purpose, growth, and impact.

The Houston-area finalists are:

  • Shannon Payne, Allied Fire Protection, Pearland
  • Jay McEntire IV, Arva Intelligence, Houston
  • Andrew Levy, Avelo Airlines, Houston
  • Derek Maetzold, Castle Biosciences, Friendswood
  • Scott Aronstein, Connectivity Source, Houston
  • Joshua Weisman, Construction Concepts, Houston
  • Feras Moussa and Ben Suttles, Disrupt Equity, Houston
  • John Poindexter, J.B. Poindexter, Houston
  • James Ross, LJA Engineering, Houston
  • Asher Kazmann, Locke Solutions, Houston
  • Chad Millis, Millis, Missouri City
  • Mike Francis, NanoTech Materials, Houston
  • Stuart Hinchen and Peter Jenkins, Quva Pharma, Sugar Land
  • Trevor Best and Suman Khatiwada, Syzygy Plasmonics, Houston
  • Hal Brumfield, Tachus Fiber Internet, The Woodlands
  • Jared Boudreaux, Vector Controls and Automation Group, Pearland
  • Ting Qiao, Wan Bridge, Houston

“The finalists of this year are audacious entrepreneurs who are making a significant impact in their respective industries and communities,” says Anna Horndahl, an EY partner and co-director of the EOY Gulf South Program.

“These pioneers, chosen by an independent panel of judges, showcase relentless commitment to their businesses, customers and communities. We are thrilled to acknowledge their accomplishments,” adds Travis Garms, an EY partner and co-director of the EOY Gulf South Program.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”